Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 May;31(5):834–836. doi: 10.1128/aac.31.5.834

Activity of phenothiazines against medically important yeasts.

Y Eilam, I Polacheck, G Ben-Gigi, D Chernichovsky
PMCID: PMC174848  PMID: 3300543

Abstract

Two phenothiazine compounds, trifluoperazine and chlorpromazine, inhibited growth in vitro of the five most common pathogenic yeasts, with MICs ranging from 10 to 40 micrograms/ml. Daily intraperitoneal injections of trifluoperazine (4 to 7 mg/kg of body weight) increased the survival of mice experimentally infected with Candida albicans or Cryptococcus neoformans. The potential use of these drugs against fungal meningitis is discussed.

Full text

PDF
834

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P. Infections in cancer patients. Cancer Treat Rev. 1975 Jun;2(2):89–128. doi: 10.1016/s0305-7372(75)80005-3. [DOI] [PubMed] [Google Scholar]
  2. Bullock W. E., Deepe G. S., Jr Medical mycology in crisis. J Lab Clin Med. 1983 Nov;102(5):685–693. [PubMed] [Google Scholar]
  3. Eilam Y. Effects of phenothiazines on inhibition of plasma membrane ATPase and hyperpolarization of cell membranes in the yeast Saccharomyces cerevisiae. Biochim Biophys Acta. 1984 Feb 15;769(3):601–610. doi: 10.1016/0005-2736(84)90059-2. [DOI] [PubMed] [Google Scholar]
  4. Eilam Y., Lavi H., Grossowicz N. Active extrusion of potassium in the yeast Saccharomyces cerevisiae induced by low concentrations of trifluoperazine. J Gen Microbiol. 1985 Oct;131(10):2555–2564. doi: 10.1099/00221287-131-10-2555. [DOI] [PubMed] [Google Scholar]
  5. Eilam Y. Membrane effects of phenothiazines in yeasts. I. Stimulation of calcium and potassium fluxes. Biochim Biophys Acta. 1983 Sep 7;733(2):242–248. doi: 10.1016/0005-2736(83)90528-x. [DOI] [PubMed] [Google Scholar]
  6. Fraser D. W., Ward J. I., Ajello L., Plikaytis B. D. Aspergillosis and other systemic mycoses. The growing problem. JAMA. 1979 Oct 12;242(15):1631–1635. [PubMed] [Google Scholar]
  7. Graybill J. R., Craven P. C. Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs. 1983 Jan;25(1):41–62. doi: 10.2165/00003495-198325010-00003. [DOI] [PubMed] [Google Scholar]
  8. Polacheck I., Zehavi U., Naim M., Levy M., Evron R. Activity of compound G2 isolated from alfalfa roots against medically important yeasts. Antimicrob Agents Chemother. 1986 Aug;30(2):290–294. doi: 10.1128/aac.30.2.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother. 1982 Sep;22(3):482–487. doi: 10.1128/aac.22.3.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs. 1983 Feb;25 (Suppl 1):35–51. doi: 10.2165/00003495-198300251-00005. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES